Telemedycyna Polska SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLTLMDC00018
PLN
0.59
-0.12 (-16.9%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 6.03% and Operating profit at -99.94% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.49
2

The company has declared Negative results for the last 4 consecutive quarters

3

Risky -

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 8 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.05

stock-summary
Return on Equity

171.51%

stock-summary
Price to Book

-7.95

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-54.26%
0%
-54.26%
6 Months
-53.54%
0%
-53.54%
1 Year
-66.85%
0%
-66.85%
2 Years
-55.97%
0%
-55.97%
3 Years
-37.23%
0%
-37.23%
4 Years
-59.86%
0%
-59.86%
5 Years
-56.3%
0%
-56.3%

Telemedycyna Polska SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
6.03%
EBIT Growth (5y)
-99.94%
EBIT to Interest (avg)
-1.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.11
Sales to Capital Employed (avg)
2.40
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
4.40%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.41
EV to EBIT
-3.62
EV to EBITDA
-4.30
EV to Capital Employed
6.75
EV to Sales
1.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.57%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 7.69% vs 0.00% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "1.30",
          "chgp": "7.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "-0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.40",
          "val2": "-0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-273.60%",
          "val2": "-299.90%",
          "chgp": "2.63%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.48% vs -6.15% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,250.00% vs 85.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.40",
          "val2": "6.10",
          "chgp": "-11.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-0.20",
          "chgp": "-1,250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-415.40%",
          "val2": "-203.50%",
          "chgp": "-21.19%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
1.40
1.30
7.69%
Operating Profit (PBDIT) excl Other Income
-0.30
-0.30
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-0.40
-0.40
Operating Profit Margin (Excl OI)
-273.60%
-299.90%
2.63%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 7.69% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
5.40
6.10
-11.48%
Operating Profit (PBDIT) excl Other Income
-2.00
-1.00
-100.00%
Interest
0.10
0.10
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-2.70
-0.20
-1,250.00%
Operating Profit Margin (Excl OI)
-415.40%
-203.50%
-21.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -11.48% vs -6.15% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,250.00% vs 85.71% in Dec 2023

stock-summaryCompany CV
About Telemedycyna Polska SA stock-summary
stock-summary
Telemedycyna Polska SA
Pharmaceuticals & Biotechnology
Telemedycyna Polska SA is a Poland-based company engaged in provision of medical services via telephone, the Internet and radio waves. It operates Kardiotele system which enables cardiologic care and checks such as electrocardiogram (EKG) through telephone connection. Kariotele is addressed to individuals, as well as to nursing homes and rehabilitation centers. As of December 31, 2011, the Company operated one wholly owned subsidiary, Centrum Nadzoru Kardiologicznego Kardiofon Sp. z o.o.
Company Coordinates stock-summary
Company Details
Ul. Ligocka 103 , KATOWICE None : 40-568
Registrar Details